Sorry, you need to enable JavaScript to visit this website.

Recently Diagnosed, Symptomatic People Who Are Immunocompromised

A COVID-19 clinical research study is underway to evaluate the safety and effectiveness of an extended course of oral PAXLOVID (nirmatrelvir/ ritonavir) for people at least 12 years of age with symptomatic COVID-19 and health conditions putting them at risk for severe illness.

Now Enrolling

To connect with a member of the study team, call 800-887-7002 and provide NCT#: NCT05438602.


About the Study for Adolescents and Adults With Symptomatic Covid-19 who are Immunocompromised

In December 2021, the FDA granted Emergency Use Authorization for a 5-day course of oral PAXLOVID (nirmatrelvir/ritonavir) to treat COVID-19 in people 12 years old (who weigh at least 40 kg) with mild-to- moderate COVID-19 who are at risk of developing severe illness. Because people with weakened immune systems or other risk factors are more likely to have prolonged or treatment-resistant COVID-19, a longer course of PAXLOVID could be more effective for these patients.

This clinical trial is evaluating if an extended 10- or 15-day course of PAXLOVID is effective and safe for adults and adolescents 12 years of age and older who currently have at least one sign/symptom of COVID-19, and who are immunocompromised.


Joining a clinical trial is an important and personal decision. Thank you for considering this study.

This study may be an option for people who:

  • Are 12 years of age or older and weigh at least 40 kg (88 lbs.)
  • Have been recently diagnosed with COVID-19 (< 5 days) and currently have at least one symptom of COVID-19
  • Are able to swallow tablets
  • Are immunocompromised

Note: There are other requirements to participate in this study. A study team member will help determine if this study is right for your family.

To connect with a member of the study team, call 800-887-7002 and provide NCT#: NCT05438602.

Header Image



All participants will receive the study drug PAXLOVID. Participants will be randomly assigned to take PAXLOVID orally twice a day for 5, 10, or 15 days.


Participants will be enrolled for about 6 months and will need to attend at least 10 study visits during this time. These visits will be completed in clinic. If in-clinic visits are not feasible, alternate locations may be allowed.


Participants may be eligible for reimbursement for their time and study-related expenses (like travel), if allowed by local regulations. Please ask the study team for more information.

Header Image